Pharvaris N.V. (PHVS), a clinical-stage company developing novel, oral therapies to treat and prevent hereditary angioedema attacks, is slated to make a poster presentation at the Western Society of Allergy, Asthma & Immunology Annual Meeting on Feb.4, 2024.
One of the posters is about the efficacy and safety of bradykinin B2 receptor antagonism with Deucrictibant immediate-release capsule (also known as PHVS416) for the treatment of hereditary angioedema (HAE) attacks based on findings from RAPIDe-1 trial.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.